The University of Texas Health Science Center at Houston (UTHSC-H) proposes to establish a Center for Clinical and Translational Sciences (CCTS) in the Texas Medical Center (TMC), Houston, Texas. Participating faculty and trainees in the CCTS will include those from the UTHSC-H component degree granting schools, including its School of Medicine, School of Public Health, Graduate School of Biomedical Sciences, School of Health Information Sciences, School of Nursing, Dental School and Institute of Molecular Medicine (IMM), as well as collaborating faculty/facilities from the UT M.D. Anderson Cancer Center (MDACC) and which also is located in the TMC. The academic """"""""home"""""""" for the CCTS will be located in 11,422 sq ft of newly renovated and CCTS-designated space at the UTH Medical School which is physically joined to the Memorial Hermann Hospital (MHH) and serves as its partner and major teaching hospital. The CCTS """"""""home"""""""" will administer all aspects of the CCTS and provide space and resources for faculty and trainees, along with expertise in study design, biostatistics, regulatory issues, ethics, and bioinformatics, and funding of Pilot and Feasibility Studies, provision of resources and protected time for clinical and translational faculty and trainees and interactions/collaborations with the various communites and industry. For Participant and Clinical Interactions Resources(PCIR), the CCTS will subsume the UTHSC-H General Clinical Research Center (GCRC) at MHH, the satellite UTHSC-H GCRC at Brownsville, Texas, and, in part, the MDACC Clinical and Translational Research Center to enhance research productivity and efficiency. In its Educational Component, the CCTS will subsume, in part, the current Center for Clinical Researchand Evidence-Based Medicine, which has developed and currently provides formal classes, mentoring, and a Masters Degree in Clinical Research (MCR) at UTHSC-H, and an active NCRR K30 award at MDACC. Also proposed in the application is a novel T32 application offering combinations of Masters and PhD degrees in Community Health Sciences,'Biomedical Sciences and/or Biomedical Informatics, primarily for pre-doctoral students, and a K12 application for post-doctoral trainees andjunior faculty. The CCTS also will subsume Core Translational Laboratories, including a enotyping/Sequencing Corel a Biomarkers Core offering DNA Microarray, RT-PCR and Proteomics services , an Immune Monitoring Core, an MRI Imaging Core, and a Biobanking Core. A CCTS """"""""Think Tank"""""""" comprised of highly accomplished translational and clinical Investigators, basic scientists and educators, and community representatives,will come together as an """"""""engine for innovation"""""""" to bring forward and recommend the application of novel and emerging scientific information, methods and technologiesto research into human health and diseases across specialties, disciplines and communities. .

Agency
National Institute of Health (NIH)
Institute
National Center for Research Resources (NCRR)
Type
Linked Specialized Center Cooperative Agreement (UL1)
Project #
3UL1RR024148-04S2
Application #
7894212
Study Section
Special Emphasis Panel (ZRR1-CR-3 (01))
Program Officer
Merchant, Carol
Project Start
2009-09-24
Project End
2011-09-23
Budget Start
2009-09-24
Budget End
2011-09-23
Support Year
4
Fiscal Year
2009
Total Cost
$396,000
Indirect Cost
Name
University of Texas Health Science Center Houston
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
800771594
City
Houston
State
TX
Country
United States
Zip Code
77225
Hodgman, E I; Cripps, M W; Mina, M J et al. (2018) External validation of a smartphone app model to predict the need for massive transfusion using five different definitions. J Trauma Acute Care Surg 84:397-402
Kennedy, Kathleen A; Mintz-Hittner, Helen A; BEAT-ROP Cooperative Group (2018) Medical and developmental outcomes of bevacizumab versus laser for retinopathy of prematurity. J AAPOS 22:61-65.e1
Rahbar, Mohammad H; Choi, Sangbum; Hong, Chuan et al. (2018) Nonparametric estimation of median survival times with applications to multi-site or multi-center studies. PLoS One 13:e0197295
Berekashvili, Ketevan; Soomro, Jazba; Shen, Loren et al. (2018) Safety and Feasibility of Argatroban, Recombinant Tissue Plasminogen Activator, and Intra-Arterial Therapy in Stroke (ARTSS-IA Study). J Stroke Cerebrovasc Dis 27:3647-3651
Rahbar, Mohammad H; Lee, MinJae; Hessabi, Manouchehr et al. (2018) Harmonization, data management, and statistical issues related to prospective multicenter studies in Ankylosing spondylitis (AS): Experience from the Prospective Study Of Ankylosing Spondylitis (PSOAS) cohort. Contemp Clin Trials Commun 11:127-135
Guo, Dong-Chuan; Regalado, Ellen S; Pinard, Amelie et al. (2018) LTBP3 Pathogenic Variants Predispose Individuals to Thoracic Aortic Aneurysms and Dissections. Am J Hum Genet 102:706-712
Gill, Clarence; Vatcheva, Kristina P; Pan, Jen-Jung et al. (2017) Frequency of Nonalcoholic Fatty Liver Disease and Subclinical Atherosclerosis Among Young Mexican Americans. Am J Cardiol 119:1717-1722
Wu, Minghua; Baron, Murray; Pedroza, Claudia et al. (2017) CCL2 in the Circulation Predicts Long-Term Progression of Interstitial Lung Disease in Patients With Early Systemic Sclerosis: Data From Two Independent Cohorts. Arthritis Rheumatol 69:1871-1878
Barreto, Andrew D; Ford, Gary A; Shen, Loren et al. (2017) Randomized, Multicenter Trial of ARTSS-2 (Argatroban With Recombinant Tissue Plasminogen Activator for Acute Stroke). Stroke 48:1608-1616
Bupathi, Manojkumar; Hajjar, Joud; Bean, Stacie et al. (2017) Incidence of infusion reactions to anti-neoplastic agents in early phase clinical trials: The MD Anderson Cancer Center experience. Invest New Drugs 35:59-67

Showing the most recent 10 out of 645 publications